Metformin IN Asthma for Overweight and Obese Individuals (MINA)
Start Date
12/9/2024
Completion Date
12/31/2028
Summary
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Detailed Description
This is a randomized, placebo-controlled, parallel-arm pilot clinical trial. Adult participants who are overweight or obese and have not well-controlled asthma despite use of an inhaled corticosteroid will be randomized to metformin, an FDA-approved medication for the treatment of type 2 diabetes mellitus, or to placebo, to be taken daily for a total duration of six months. Recruitment will occur at two sites in the United States. Randomized participants will have regular telemedicine visits to assess side effects and adherence. Additionally, participants will have a measurement of asthma outcomes at randomization and at 3 and 6 months after randomization. The purpose of this study is to determine feasibility to inform a future multi-center clinical trial of metformin in this population.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Metformin hydrochloride extended-release tablets
Visually identical placebo Metformin hydrochloride extended-release tablets
Conditions
Locations
Johns Hopkins University
Baltimore, Maryland 21224
United States
Baylor College of Medicine
Houston, Texas 77030
United States